Junshi Reports NMPA’s Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

July 30, 2021 Auto Bot Pharma 0

Shots:

  • The sNDA is based on the P-III JUPITER-06 study evaluating toripalimab + CT vs PBO + CT in 514 patients with locally advanced or metastatic ESCC
  • The results of the study showed that toripalimab + CT significantly improved both PFS and OS for patients with advanced or metastatic ESCC, regardless of PD-L1 expression status. The data will be presented soon at ESMO 2021
  • Toripalimab is the first domestic anti-PD-1 mAb obtaining marketing approval in China and has additionally received BTD, FTD & ODD from FDA for the treatment of mucosal melanoma, nasopharyngeal carcinoma, and soft tissue sarcoma

Click here to read full press release/ article | Ref: Globe Newswire | Image: PR Newswire

The post Junshi Reports NMPA’s Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma first appeared on PharmaShots.